关键词：乙型肝炎；炎性病症；嗜肝DNA；病毒家族
摘 要：Hepatitis B is an inflammatory condition that occurs as a result of infection with hepatitis B virus.The hepatitis B virus is an enveloped virus that belongs to the Hepadnavirus family. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of liver cells. Following viral infection, the immune system is activated against the virus and hepatocytes infected with viruses. This, in turn, leads to inflammation of the liver. Extrahepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread in highly endemic areas. The age of a person at the time of infection and the infecting dose of the virus are important factors that determine the severity of acute or chronic hepatitis B. Most patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Hepatitis B: Acute and Chronic Infections

06.2 Hepatitis B: Geographical Distribution

06.3 Hepatitis B: Estimated National Immunization

Coverage

06.3.1 Hepatitis B Birth Dose Vaccine

06.3.2 Third Dose of Hepatitis B Vaccine

06.4 Individuals at Risk of Chronic Hepatitis B

06.5 Hepatitis B: Diagnosis

06.5.1 Serological Markers

06.5.2 Hepatitis B Serologic Test Interpretation

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Market Segmentation by Composition

08.1 Mono Vaccines

08.2 Combination Vaccines

09. Market Segmentation by End-user Age

Group

09.1 Global Adult Hepatitis B Vaccines Market

09.1.1 Market Size and Forecast

09.1.2 Geographical Segmentation

09.2 Global Pediatric Hepatitis B Vaccines Market

09.2.1 Market Size and Forecast

10. Geographical Segmentation

10.1 Hepatitis B Vaccines Market in the Americas

10.1.1 Market Size and Forecast

10.2 Hepatitis B Vaccines Market in the EMEA Region

10.2.1 Market Size and Forecast

10.3 Hepatitis B Vaccines Market in the APAC Region

10.3.1 Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.2.1 GlaxoSmithKline

18.2.2 Merck

18.2.3 Sanofi Pasteur

18.3 Other Prominent Vendors and Future Players

19. Late-stage Pipeline Candidates

19.1 Key Information on Late-stage Pipeline

Candidates

19.1.1 PR5I

19.1.2 Heplisav-B

20. Key Vendor Analysis

20.1 GlaxoSmithKline

20.1.1 Key Facts

20.1.2 Business Overview

20.1.3 Business Segmentation

20.1.4 Business Segmentation by Revenue 2012 and 2013

20.1.5 Geographical Segmentation by Revenue 2013

20.1.6 Pipeline Products

20.1.7 Business Strategy

20.1.8 Key Information

20.1.9 SWOT Analysis

20.2 Merck

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation by Revenue 2013

20.2.4 Business Segmentation by Revenue 2012 and 2013

20.2.5 Geographical Segmentation by Revenue 2013

20.2.6 Business Strategy

20.2.7 Key Developments

20.2.8 SWOT Analysis

20.3 Sanofi Pasteur

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Strategy

20.3.4 Recent Developments

20.3.5 SWOT Analysis

21. Other Reports in this Series